Varenicline Versus Bupropion SR or Placebo for Smoking Cessation: A Pooled Analysis
Methods : Smokers in 2 randomized, placebo-controlled trials received varenicline 1 mg BID (n696), bupropion SR 150 mg BID (n671), or placebo (n685) for 12 weeks. Nontreatment followup lasted 40 weeks.
Results : CAR912 was greater for varenicline (44.0) versus bupropion SR (29.7; P<0.0001) and placebo (17.7; P<0.0001). CAR912 for varenicline versus placebo was not affected by age, gender, or nicotine dependence level.
Conclusions : Varenicline was more efficacious than bupropion SR or placebo. Varenicline's efficacy versus placebo was not influenced by factors predictive of abstinence.
Document Type: Research Article
Affiliations: 1 President, Los Angeles Clinical Trials, Burbank, CA.
Publication date: 2008-11-01
The American Journal of Health Behavior seeks to improve the quality of life through multidisciplinary health efforts in fostering a better understanding of the multidimensional nature of both individuals and social systems as they relate to health behaviors.
The Journal aims to provide a comprehensive understanding of the impact of personal attributes, personality characteristics, behavior patterns, social structure, and processes on health maintenance, health restoration, and health improvement; to disseminate knowledge of holistic, multidisciplinary approaches to designing and implementing effective health programs; and to showcase health behavior analysis skills that have been proven to affect health improvement and recovery.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Review Board
- Reprints and Permissions
- Ingenta Connect is not responsible for the content or availability of external websites